secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-06-01T13:06:14+00:00
Accession:  0001129928-26-000037
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned
--------------------------------------------------------------------------------

- Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.
- Company planning additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models.
- Evaluating combinations with KRAS G12C inhibitors, pan-RAS inhibitors, and next-generation RAS-targeted agents.
- Full dataset expected to be presented in fall/winter 2026.
- CEO states belief that pelareorep may serve as immune-priming backbone for next-generation targeted therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/0001129928-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/oncy-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer